A 74-year-old woman had an undifferentiated carcinoma with osteoclast-like giant cells (UCWOGC) in the body of the pancreas with massive portal vein tumor thrombus (PVTT). Because the PVTT progressed so rapidly into the right portal branch, the patient first underwent distal pancreatectomy and tumor thrombectomy to prevent life-threatening portal venous obstruction. Although a recurrent PVTT had developed early postoperatively, systemic gemcitabine treatment was so effective that it induced complete remission 5 months after the initiation of chemotherapy. The patient continued to be in complete response for 12 months, and has survived for 19 months since surgery.
Introduction
Undifferentiated carcinoma of the pancreas is a rare and aggressive tumor; accounts for 2-7% of all pancreatic cancers (1) (2) (3) (4) . The prognosis of undifferentiated carcinoma of the pancreas is worse than that of poorly differentiated ductal adenocarcinoma of the pancreas (5). Paal et al. reported that 29 of 35 patients with undifferentiated carcinoma of the pancreas died with an average survival of 5.3 months (3). Among these carcinomas, undifferentiated carcinoma with osteoclast-like giant cells (UCWOGC) consists of osteoclastlike multinucleated giant cells within mononuclear stromal cells. These giant cells are similar to giant cell tumors of bone (6, 7) , which are positive for CD68, as a specific marker of the monocyte phagocytic system (8), but negative for epithelial markers (9, 10) . Compared to undifferentiated carcinoma, which indicates carcinoma without osteoclast-like giant cells, UCWOGC of the pancreas has a favorable survival prognosis (11) . A mean survival of 12 months has reported (12) , with operation being the primary treatment in most cases. However, there is no standard treatment regimen for advanced or recurrent UCWOGC.
Portal vein tumor thrombus (PVTT) frequently occurs in advanced hepatocellular carcinomas (32% of cases) and in metastatic liver tumor (5% of cases) considering all tumors complicated by PVTT (13) . Pancreatic ductal adenocarcinoma often spreads to the portal vein, but it rarely progresses to PVTT (14) . Yamato et al. summarized the literature of 18 cases of pancreatic tumor with PVTT, none of which involved undifferentiated carcinoma (15) . Since then, there have been two case reports of UCWOGC of the pancreas with PVTT (16, 17) .
We present a case of successful treatment for the PVTT in the setting of UCWOGC of the pancreas in which chemotherapy with gemcitabine resulted in complete response. 
Case Report
A 74-year-old woman presented with a poor appetite and epigastric pain. There was no significant past medical history. After a tumor was detected in the body of the pancreas by ultrasonography (US), the patient was admitted to our hospital. Blood examination revealed slight anemia and elevation of pancreatic enzymes. Carcinoembryonic antigen and carbohydrate antigen 19-9 were not elevated ( Table 1 ). An abdominal computed tomography (CT) scan revealed a tumor measuring 35 mm in diameter in the body of the pancreas (Fig. 1A) , with mixed high-density and low-density areas. These CT findings were consistent with a mucinous cystic neoplasm of the pancreas. There was no evidence of distant metastases or liver metastasis, but a low-density area was detected in the splenic vein (Fig. 1A) . Therefore, anticoagulation therapy was started given the suspicion of thrombosis. Endoscopic retrograde cholangiopancreatography revealed that the tumor occupied a part of main pancreatic duct, and subsequent cytology revealed class II. Four weeks after initiation of anticoagulation therapy, follow-up CT showed that the main tumor had become enlarged to 52 mm and that the low-density area in the splenic vein extended to the right branch of the portal vein (Fig. 1B) . In addition to the main tumor, magnetic resonance imaging depicted a mass in the portal vein as a high-intensity lesion, not only on T2-weighted image but also diffusion-weighted image (Fig. 1C, D) . Thus, a diagnosis of PVTT was made. Given these findings as well as the rapid progression, we planned distal pancreatectomy with thrombectomy of the PVTT to prevent acute portal vein obstruction; if portal vein obstruction extends to mesenteric venous arches, which often occurs in the acute phase, mortality due to intestinal infarction can be as high as 50% (18, 19) . To achieve cura- tive resection, total pancreatectomy with concomitant resection of the right liver and portal reconstruction was necessary. However, in view of the general prognosis of advanced pancreas cancer, such a surgery seemed too invasive for the patient.
Intraoperatively, we confirmed the PVTT in the right branch of the portal vein by US. After performing a portosystemic bypass, we opened the portal vein trunk longitudinally and removed as much as possible of the PVTT which was in the portal vein trunk and in the right portal branch (Fig. 2A) . The primary tumor was grossly yellowish white with coagulated blood (Fig. 2B) . Histological examination of the tumor showed that it was composed of pleomorphic to spindle-shaped cells, and also scattered non-neoplastic osteoclast-like giant cells (Fig. 3A) , which stained positively for CD68 (Fig. 3B) . The main tumor cells and the giant cells were diffusely positive for vimentin (Fig. 3C) . Cytokeratin AE1/AE3 was partially positive in the tumor cells but not in the giant cells (Fig. 3D) . According to these characteristic features, the tumor was diagnosed as UCWOGC. The removed PVTT showed the same histological result.
One month postoperatively, repeat CT showed a fine low- density area in the right branch of the portal vein (Fig. 4A) , which increased in size after a scan one month later (Fig. 4B) , suggesting a recurrence of PVTT. Chemotherapy with gemcitabine was initiated, as a prior report demonstrated its efficacy in UCWOGC (20) . Gemcitabine was administered with a protocol of 1,000 mg/m 2 weekly for three weeks followed by one week of rest. The PVTT shrank 2 months after initiation of chemotherapy (Fig. 4C) and was in complete remission on CT at 5 months (Fig. 4D) . Gemcitabine administration was skipped 4 times because of neutropenia with a grade of toxicity over 2 (neutrophil count < 1,500/mm 3 ) according to the National Cancer Institute Toxicity Criteria version 2, but it was continued for 16 courses without dose reduction. The patient continued to be in complete remission for 12 months, and has survived for 19 months since surgery (Fig. 4E) .
Discussion
UCWOGC of the pancreas was reported first by Rosai in 1968 as "carcinoma of the pancreas simulating giant cell tumor bone" (21) . The origin of these osteoclast-like giant cells has yet to be determined. Molberg et al. reported nine cases in which osteoclast-like giant cells were positive for CD68 and negative for cytokeratins AE1/AE3 and P53 (10) . This immunohistochemical profile supports a reactive histiocytic lineage of the non-neoplastic osteoclast-like giant cells. In the present case, immunohistochemistry showed that the giant cells were positive for CD68 and vimentin. On the other hand, mononuclear carcinoma cells were slightly positive for cytokeratin AE1/AE3, which was not detected in giant cells, consistent with the previously reported lineage of origin (10). Maksymov et al. reported that UCWOGC of the pancreas involved pancreatic ductal structures in varying degrees (22) . Their finding may be explained by a coexistence with intraductal papillary mucinous neoplasm (23, 24) . These observations support that UCWOGC of the pancreas may develop from carcinoma in situ within the main pancreatic duct or its branches (22) . Therefore, the tumor may be of epithelial origin coexisting in the presence of cells of mesenteric differentiation.
Yamato et al. reviewed 18 cases of pancreatic tumors forming PVTT, which were reported in the English language literature between 1985 and 2007 (15) . Pathologic classification of these 18 cases were 7 cases of endocrine tumor (38.9%), 3 cases of invasive ductal carcinoma (16.7%), 2 cases of acinar cell carcinoma (11.1%), 2 cases of intraductal papillary mucinous carcinoma (11.1%) and 1 case each for melanoma and pancreatoblastoma. The outcome of surgically treated patients was favorable compared to that of nonsurgical treatments, even in pancreatic ductal adenocarcinoma. Hence, if possible, surgical treatment in cases of PVTT is desirable irrespective of the cell of origin. In their report, UCWOGC of the pancreas was not included. However, as previously stated there are two case reports of UCWOGC of the pancreas forming PVTT, with Isaka et al. reporting the first case of UCWOGC forming PVTT (16) . In their patient, the tumor size was 10 cm in diameter and PVTT extended from the splenic vein to the confluence of superior mesenteric vein. The patient underwent distal pancreatectomy with removal of PVTT and no recurrence was noted at approximately 13 months after surgery. Nara reported the second case of UCWOGC of the pancreas forming PVTT in 2009 (17) . The tumor in his report was 11.6 cm in diameter. Because the tumor formed PVTT and spread to the main pancreatic duct, the patient underwent total pancreatectomy with partial resection of the portal vein. The patient had no recurrence 14 months after surgery. In these two cases, nothing was reported with regard to adjuvant chemotherapy. These results suggest that UCWOGC of the pancreas, even with PVTT, would be treated by surgery.
The differential diagnosis between PVTT and portal vein thrombosis (PVT) is rather difficult. In the present patient, the mass in the portal vein was also detected as uniform low-density area on enhanced CT, and therefore PVT in the chronic stage was first suspected. However, this mass was visualized in magnetic resonance imaging (MRI) as a highintensity area on T2-weighted image and also on diffusionweighted image. On MRI, the PVT in the chronic stage should be detected as an iso-intensity area on T2-weighted image, which is influenced by extra cellular methaemoglobin, and as a low-intensity area on diffusion-weighted image. The discrepancy of the MRI findings in the present patient from those PVT characteristics led us to re-consider the mass as PVTT instead of PVT. In this way, the differential diagnosis between PVTT and PVT would be inclusively determined by CT and MRI.
Although fortunately liver metastasis did not occur in the present patient, the incidence of liver metastasis in cases with PVTT appears to be much higher than in those cases without PVTT (25) . In patients of UCWOGC of the pancreas with liver metastasis, primary surgical treatment is not indicated in general. However, there has been no standard regimen for undifferentiated carcinoma. Wakatsuki et al. reported a case of undifferentiated carcinoma without osteoclast-like giant cells, showing complete response to cisplatin/paclitaxel treatment (26) . In their report, the primary lesions and lymph node metastases had completely disappeared on CT after two cycles. Their patient has been disease free for 23 months since initial chemotherapy. On the other hand, with regard to UCWOGC of the pancreas, to date the report of Bauditz et al. is the only report (27) . Their patient with liver metastases received palliative chemotherapy using a combination with cisplatin, etoposide and ifosfamide and partial response was achieved. In the vicinity of the pancreas, Matsuzawa et al. reported a case of surgically resected UCWOGC in the periampullary region (20) . The tumor recurred in the liver and para-aortic lymph nodes 6 months post-pancreaticoduodenectomy, and gemcitabine achieved complete response of the cancer. The present report seems to be the first case in which gemcitabine resulted in complete response of UCWOGC of the pancreas with PVTT based on CT imaging, now 19 months postoperative. The chemotherapy regimens of these reports are summarized in Table 2 . These results suggest that gemcitabine may be an effective regimen for treating UCWOGC. Although it was not the case in the present patient, if a patient has both PVTT and liver metastasis, priority of surgical removal of PVTT or chemotherapy might depend on the risk of acute obstruction of portal system.
In conclusion, surgery would play a significant role in the initial treatment for patients with advanced UCWOGC of the pancreas with PVTT. In cases whereby the cancer is unresectable or recurrent, chemotherapy with gemcitabine would be a feasible treatment option.
The authors state that they have no Conflict of Interest (COI).

